Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

The research, funded by Parkinson's UK, reveals that an experimental drug, tasquinimod, originally developed for prostate cancer, may have the potential to treat Parkinson's disease.

Image taken by the team of Parkinson’s stem cell-derived neurons growing

The Oxford Parkinson's Disease Centre team, in a study led by Professor Richard Wade-Martins and Professor Caleb Webber, have found compelling evidence that an experimental cancer drug may have the potential to treat Parkinson's disease.

Their research, funded by Parkinson's UK, suggests that tasquinimod, a drug not yet on the market, works by interacting with a key protein inside brain cells called HDAC4. This interaction controls the activity of genes that may be critical in the development of Parkinson's. 

The team are using pioneering stem cell techniques to grow brain cells from skin cell samples, donated by both people with and without the condition.

 

More information is available on the Parkinson's UK website and the Parkinson's UK Research Blog

More detail is also available on The University of Oxford website.

Read the full Cell Stem Cell paper here.

Similar stories

Blood bank storage can reduce ability of transfusions to treat anaemia

New research from the Swietach Group in collaboration with NHS Blood and Transplant has demonstrated that the process of storing blood in blood banks can negatively impact the function of red blood cells and consequently may reduce the effectiveness of blood transfusions, a treatment commonly used to combat anaemia.

Overlapping second messengers increase dynamic control of physiological responses

New research from the Parekh and Zaccolo groups reveals that a prototypical anchoring protein, known to be responsible for regulating several important physiological processes, also orchestrates the formation of two important universal second messengers.

Feeling tired? Here’s how the brain’s ‘hourglass’ controls your need for sleep – new research

New article on The Conversation website written by Dr Lukas Krone, Associate Professor Vladyslav Vyazovskiy and Professor Zoltán Molnár.

Scientists Decipher How NeuroImmune Interactions Burn Deep Fat

A pioneering collaborative mouse study from an international team of researchers including DPAG's Associate Professor Ana Domingos published in Nature offers new therapeutic avenues for reducing visceral fat stores, which have been associated with cardiovascular disease and multiple types of cancer.

Study set to detect hidden lung damage in Long Covid Patients

Following the successful identification of long-term previously invisible lung damage in post-Covid patients, a large NIHR grant will enable a University of Oxford team including DPAG's Dr James Grist to continue this crucial work to shed light on why people with confirmed Long Covid continue to experience breathlessness following recovery from Covid-19.